{"id":"NCT01554982","sponsor":"Keryx Biopharmaceuticals","briefTitle":"A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis","officialTitle":"A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-06","completion":"2014-08","firstPosted":"2012-03-15","resultsPosted":"2016-07-13","lastUpdate":"2016-07-13"},"enrollment":168,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["End Stage Renal Disease","Kidney Failure","Renal Failure","Hyperphosphatemia","ESRD"],"interventions":[{"type":"DRUG","name":"ferric citrate","otherNames":["Auryxia","KRX-0502"]}],"arms":[{"label":"Ferric Citrate","type":"OTHER"}],"summary":"A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.","primaryOutcome":{"measure":"Safety Parameters","timeFrame":"48 Weeks","effectByArm":[{"arm":"Ferric Citrate","deltaMin":142,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":34,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":166},"commonTop":["Diarrhoea","Nausea","Vomiting","Faeces discoloured","Headache"]}}